Ionis Pharmaceuticals, Inc. Form 4 Filings

Ionis Pharmaceuticals executive Patrick R. O'Neil acquired additional common shares through an employee stock purchase plan. On February 27, 2026, he purchased 376 shares of Ionis common stock at an average price of $48.8665 per share under the Amended and Restated 2000 Employee Stock Purchase Plan. Following this transaction, his direct holdings increased to 72,359 common shares, and the newly purchased shares cannot be sold until August 27, 2026.

IONIS PHARMACEUTICALS INC CEO Brett P. Monia acquired 484 shares of common stock on February 27, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $48.8665 per share. After this transaction, the CEO directly owns 254,981 shares. These shares may not be sold until August 27, 2026.

Ionis Pharmaceuticals executive Brian Birchler reported an employee stock purchase transaction. On February 27, 2026, he purchased 351 shares of Ionis common stock at an average price of $48.8665 per share under the company’s Amended and Restated 2000 Employee Stock Purchase Plan, bringing his direct holdings to 66,598 shares. These shares may not be sold until August 27, 2026.

Ionis Pharmaceuticals executive Frank Bennett, EVP and Chief Scientific Officer, reported a small personal share purchase through the company’s employee stock purchase plan. On February 27, 2026, he acquired 261 shares of Ionis common stock at $48.8665 per share under the Amended and Restated 2000 Employee Stock Purchase Plan.

Following this transaction, Bennett directly owns 100,554 common shares. According to the filing, these newly purchased shares are subject to a holding period and may not be sold until August 27, 2026, which temporarily restricts his ability to dispose of this specific block of stock.

Ionis Pharmaceuticals executive files corrective Form 4/A. EVP and Chief Scientific Officer C. Frank Bennett reports that an earlier filing on February 4, 2026 mistakenly showed a sale of 20,000 common shares and the exercise of 65,089 stock options. These transactions were executed in error and fully reversed on February 12, 2026.

Following the reversal, Bennett is shown as directly beneficially owning 100,293 shares of Ionis Pharmaceuticals common stock as of February 12, 2026. The current filing uses a corrective "J" transaction code with zero shares at a price of $0.0 to document the adjustment.

Ionis Pharmaceuticals EVP Research Eric Swayze reported preset stock sales. On February 13, 2026, he executed two open-market sales of Ionis common stock under a Rule 10b5-1 trading plan adopted on August 14, 2024.

The transactions totaled 9,435 shares at $81.5592 and 6,207 shares at $82.0691 weighted-average prices. After these sales, Swayze held 32,105 shares directly and 318 shares indirectly through his son.

Ionis Pharmaceuticals director B. Lynne Parshall reported an open-market sale of common stock. On February 11, 2026, Parshall sold 5,000 shares of Ionis common stock at a weighted average price of $82.7177 per share under a pre-established Rule 10b5-1 trading plan adopted on May 6, 2025. After this transaction, Parshall directly beneficially owns 56,344 shares of Ionis common stock.

Ionis Pharmaceuticals Inc. Chief Executive Officer and director Brett P. Monia reported selling 29,430 shares of common stock on February 6, 2026 at a weighted average price of $85.7907 per share. The sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on August 13, 2024. Following this transaction, Monia beneficially owned 254,497 shares of Ionis common stock in direct form.

Ionis Pharmaceuticals executive C. Frank Bennett reported option exercises and stock sales. As EVP and Chief Scientific Officer, he exercised non-qualified stock options for 48,626 shares at $60.89 and 16,463 shares at $32.6, then converted them into common stock.

On the same date, he sold 20,000 shares at a weighted-average price of $82.599 and sold 48,626 and 16,463 shares at a weighted-average price of $83.0284, in multiple trades within disclosed price ranges. After these transactions, he directly owned 80,293 common shares and 2,406 option shares.

Ionis Pharmaceuticals executive Eric Swayze reported equity transactions in company stock. On January 29, 2026, he acquired 11,991 shares of common stock at $0.0 per share from the vesting of performance-based restricted stock units, after the Compensation Committee certified achievement of the relative total shareholder return goal at 167.27% of target shares.

On January 30, 2026, he sold 6,179 shares of Ionis common stock at a weighted average price of $82.9335 per share, in multiple transactions within a narrow price range. Following these transactions, he directly beneficially owned 47,747 shares, and an additional 318 shares were held indirectly by his son.

Ionis Pharmaceuticals executive Eugene Schneider reported two stock transactions. On January 29, 2026, he acquired 11,991 shares of common stock at $0.00 when performance-based restricted stock units vested. The Compensation Committee certified performance at 167.27% of target shares based on relative total shareholder return.

On January 30, 2026, Schneider sold 6,179 shares of common stock at a weighted average price of $83.4487, in multiple trades between $83.32 and $83.48. After these transactions, he directly owned 69,702 shares of Ionis common stock.

Ionis Pharmaceuticals EVP, CLO & General Counsel Patrick R. O'Neil reported an equity award vesting and a share sale. On 01/29/2026 he acquired 11,991 shares of common stock at $0.0 upon vesting of performance-based RSUs, after the Compensation Committee certified performance at 167.27% of target shares. On 01/30/2026 he sold 6,179 common shares at a weighted average price of $83.5335 per share in multiple trades between $83.48 and $83.67. Following these transactions, he directly owned 71,983 Ionis common shares.

Ionis Pharmaceuticals CEO Brett P. Monia reported two stock transactions. On January 29, 2026, he acquired 122,214 shares of common stock at $0.00 upon vesting of performance-based restricted stock units. These PRSUs vested at 167.27% of target, based on Ionis’s relative total shareholder return versus a peer group.

On January 30, 2026, Monia sold 62,970 shares of Ionis common stock at a weighted average price of $82.7216, from multiple trades between $82.26 and $82.925. After these transactions he directly owned 283,927 shares of Ionis common stock.

Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported two stock transactions. On January 29, 2026, she acquired 13,562 shares of common stock at $0.00 per share from the vesting of performance-based restricted stock units tied to relative total shareholder return, which vested at 167.27% of target shares. On January 30, 2026, she sold 6,988 shares of common stock at a weighted average price of $83.243 per share, with individual sale prices ranging from $83.11 to $83.32. Following these transactions, she directly owned 132,881 shares of Ionis Pharmaceuticals common stock.

Ionis Pharmaceuticals executive Brian Birchler reported an equity award and a share sale. On 01/29/2026, he acquired 11,991 shares of common stock at $0.0 per share upon vesting of performance-based restricted stock units tied to relative total shareholder return, which vested at 167.27% of target.

On 01/30/2026, Birchler sold 6,179 common shares at a weighted average price of $83.0309, in multiple trades between $83.00 and $83.08. After these transactions, he directly owned 66,247 Ionis shares as EVP, Corp and Development Ops.

Ionis Pharmaceuticals executive C. Frank Bennett reported a mix of equity vesting and share sales. On January 29, 2026, he acquired 11,421 shares of common stock at $0.0 upon vesting of performance-based restricted stock units. The Compensation Committee certified performance at 167.27% of target shares based on relative total shareholder return versus a peer group, within a possible payout range of 0% to 200%.

On January 30, 2026, Bennett sold 5,885 shares of common stock at a weighted average price of $82.9466, from multiple trades between $82.94 and $82.95. After these transactions, he directly owned 100,293 shares of Ionis common stock.

Ionis Pharmaceuticals executive Joseph Baroldi, EVP and Chief Business Officer, reported equity compensation and a stock sale. On January 29, 2026, he acquired 10,278 shares of common stock at $0.0 upon vesting of performance-based restricted stock units, after performance was certified at 167.27% of target shares based on relative total shareholder return.

On January 30, 2026, he sold 5,296 shares of Ionis common stock at a weighted average price of $82.9615 per share, in multiple trades between $82.95 and $82.97. After these transactions, he held 45,413 shares directly, plus 4,772 shares indirectly through his spouse.

Ionis Pharmaceuticals executive Shannon L. Devers sold 3,977 shares of common stock on January 22, 2026 under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $81.3403 per share, with individual trades executed between $81.33 and $81.37. After this transaction, Devers beneficially owns 22,541 shares of Ionis Pharmaceuticals common stock in direct form.

Ionis Pharmaceuticals director Michael J. Yang reported the vesting of restricted stock units and corresponding receipt of common shares. On 01/15/2026, 1,930 Restricted Stock Units were converted at an exercise price of $0.0 into 1,930 shares of Ionis common stock, reflecting the scheduled vesting of an equity award. Following these transactions, Yang beneficially owned 7,150 Restricted Stock Units and 7,940 shares of common stock, all held directly. The filing notes that each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock or its cash equivalent, and that these units vest in three equal annual installments.

Ionis Pharmaceuticals EVP Research Eric Swayze reported equity award activity and related stock sales. On January 15, 2026, restricted stock units vested, resulting in the acquisition of 21,366 shares of common stock at $0.0 per share, after which he held 51,819 shares directly. On January 16, 2026, he sold 9,884 shares of common stock at a weighted average price of $75.34 in an automatic sale to cover tax withholding, leaving 41,935 shares held directly. An account for his son held 318 shares after a sale of 49 shares.

He received a grant of 25,800 performance restricted stock units, representing the maximum earnable based on a three-year total shareholder return performance period, and 9,675 additional restricted stock units. His son was granted 225 restricted stock units. Each unit represents a contingent right to one share of Ionis common stock or its cash value, generally vesting in four equal annual installments.

Ionis Pharmaceuticals executive Eugene Schneider, EVP and Chief Clinical Development Officer, reported a mix of stock grants, vesting, and a sale. On 01/15/2026, 21,685 restricted stock units vested and were converted into common shares at an exercise price of $0.0, increasing his directly held common stock to 73,192 shares.

On the same date, he received a grant of 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum 200% of target that may be earned after a three-year performance period based on relative total shareholder return, and a separate grant of 9,675 time-based RSUs that vest in four equal annual installments. On 01/16/2026, 9,302 common shares were sold at a weighted average price of $75.59 in an automatic sale to cover tax withholding obligations under the company’s equity plan, leaving him with 63,890 common shares directly owned, along with derivative holdings of PRSUs and RSUs.

Ionis Pharmaceuticals executive Patrick R. O'Neil, EVP, CLO & General Counsel, reported several equity transactions in Ionis common stock and equity awards.

On 01/15/2026, 21,473 shares of common stock were acquired at $0.0 upon vesting and release of Restricted Stock Units, increasing his directly held common stock to 75,362 shares. The same day, derivative positions changed as 25,800 Performance Restricted Stock Units were granted at $0.0, representing the maximum that may be earned after a three-year performance period tied to relative total shareholder return, and 9,675 additional Restricted Stock Units were granted.

On 01/16/2026, O'Neil sold 9,191 shares of common stock at a weighted average price of $75.84 in an automatic sale to cover tax withholding obligations under the company’s equity plan, leaving 66,171 common shares directly owned.

Ionis Pharmaceuticals Chief Executive Officer and director Brett P. Monia reported multiple equity award transactions and a related share sale. On January 15, 2026, 89,145 shares of common stock were acquired at $0.0 per share through the vesting and release of previously granted restricted stock units, increasing his directly held common stock to 268,717 shares. On the same day, he received 113,880 Performance Restricted Stock Units (PRSUs), representing the maximum earnable amount based on a three-year performance period, and 42,705 additional restricted stock units under the company’s equity incentive plan.

On January 16, 2026, Monia sold 44,034 common shares at a weighted average price of $74.82 per share in an automatic sale to cover required tax withholding obligations tied to the RSU vesting. Following these transactions, he directly beneficially owned 224,683 shares of common stock, alongside substantial outstanding PRSU and RSU awards that may convert into shares or cash in the future based on vesting and performance conditions.

Ionis Pharmaceuticals executive Holly Kordasiewicz reported a stock option grant under the company’s equity incentive plan. On 01/02/2026, she received a non-qualified stock option to purchase 7,500 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share.

According to the filing, none of these options were exercisable on the grant date. 25% of the option shares will vest and become exercisable on 01/02/2027, with the remaining shares vesting in 36 equal monthly installments over the following three years, so full vesting occurs over four years. After this grant, Kordasiewicz beneficially owned 16,600 stock options in total, held directly.

Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, reported multiple equity transactions. On 01/15/2026, 11,119 shares of common stock were acquired at $0.0 per share through the vesting and release of previously granted restricted stock units. On 01/16/2026, 4,141 shares were sold at a weighted average price of $75.66 per share in an automatic sale to cover tax withholding obligations under the company’s equity incentive plan, leaving 14,718 common shares directly owned.

On the derivative side, restricted stock units were exercised or granted at $0.0 per unit on 01/15/2026. An RSU conversion of 11,119 units reduced the RSU balance to 20,830 units. Additional grants of 13,650 and 11,250 RSUs increased the total RSU holdings to 45,730 units. Each RSU represents the right to receive one share of Ionis common stock or its cash equivalent, vesting in four equal annual installments.

Ionis Pharmaceuticals executive Kyle Jenne reported equity award activity and a small stock sale. On January 15, 2026, Jenne acquired 7,013 shares of common stock at $0.00 through the vesting and release of previously granted restricted stock units. The filing shows he then held 18,212 common shares directly.

On the same date, he received 25,800 performance restricted stock units, representing the maximum that may be earned over a three-year period based on Ionis’s relative total shareholder return, and 9,675 time-based restricted stock units that vest in four equal annual installments. On January 16, 2026, Jenne sold 1,823 shares of common stock at a weighted average price of $75.96, in an automatic sale to cover tax-withholding obligations, leaving him with 16,389 common shares held directly.

Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported several equity award transactions and a small share sale. On January 15, 2026, 28,729 Restricted Stock Units (RSUs) vested and were converted into common stock at an exercise price of $0.0, and she received a new grant of 34,360 Performance RSUs and 12,885 RSUs under the company’s 2011 Equity Incentive Plan. The performance units may vest after a three-year period based on relative total shareholder return, with the amount reported representing the maximum that can be earned.

On January 16, 2026, she sold 12,922 shares of common stock at a weighted average price of $75.22 to cover tax withholding obligations related to the RSU vesting. After these transactions, she directly held 126,307 shares of common stock, 120,995 Performance RSUs, and 68,825 RSUs.

Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, reported multiple equity transactions in January 2026. On January 15, 2026, 17,377 shares of common stock were acquired upon vesting of restricted stock units at an exercise price of $0.0, and on January 16, 2026, 8,353 shares of common stock were sold in an automatic sale to cover tax withholding at a weighted average price of $75.95.

Devers also received 25,800 Performance Restricted Stock Units, representing the maximum that may be earned based on a three-year performance period, and 9,675 Restricted Stock Units that vest in four equal annual installments. Following these transactions, she directly beneficially owned 26,518 shares of common stock, 47,800 Performance RSUs, and 52,704 RSUs, each RSU representing a contingent right to one share of Ionis common stock or its cash equivalent.

Ionis Pharmaceuticals executive Brian Birchler reported several equity transactions. On January 15, 2026, 20,089 shares of common stock were acquired at $0.0 per share upon vesting and release of restricted stock units, increasing his direct holdings to 68,915 shares. On January 16, 2026, he sold 8,480 shares of common stock at a weighted average price of $75.11 per share in an automatic sale to cover tax withholding, leaving 60,435 common shares directly owned.

Birchler also received equity awards on January 15, 2026, including 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum that may be earned based on three‑year relative total shareholder return, and a grant of 9,675 Restricted Stock Units (RSUs). These PRSUs may vest at the end of the three‑year period, while RSUs generally vest in four equal annual installments, each unit representing a right to one share of Ionis common stock or its cash equivalent.

Ionis Pharmaceuticals executive C. Frank Bennett, EVP and Chief Scientific Officer, reported multiple equity transactions. On January 15, 2026, 21,055 shares of common stock were acquired at $0.0 per share through the vesting and release of restricted stock units, increasing his direct common stock holdings to 103,734 shares. On January 16, 2026, he sold 8,977 shares of common stock at a weighted average price of $75.15 per share in an automatic sale to cover tax withholding obligations, leaving 94,757 shares owned directly.

He was also granted 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum that may be earned based on a three-year relative total shareholder return performance period, and 9,675 Restricted Stock Units (RSUs) that vest in four equal annual installments. Each RSU or PRSU represents a contingent right to receive one share of Ionis common stock or its cash equivalent.

Ionis Pharmaceuticals executive Joseph Baroldi reported equity award activity and related share sales. On 01/15/2026, restricted stock units vested, resulting in the acquisition of 17,037 shares of common stock directly and 2,850 shares indirectly through his spouse at an exercise price of $0.0 per share. Following these transactions, he held 47,338 common shares directly and 5,921 shares indirectly through his spouse.

On 01/16/2026, he reported sales of 6,907 directly held shares at a weighted average price of $75.75 and 1,149 indirectly held shares at $75.78, described as automatic sales to cover tax withholding obligations. Separately, on 01/15/2026 he received a grant of 25,800 performance restricted stock units that may vest after a three‑year performance period, as well as additional restricted stock unit grants for himself and his spouse under the company’s equity incentive plan.

Ionis Pharmaceuticals' EVP and Chief Human Resources Officer, Shannon L. Devers, reported a series of option exercises and share sales on January 7, 2026. Devers exercised several non-qualified stock options to acquire common stock at exercise prices of $32.60, $37.58, $52.87, and $56.78, then sold the resulting shares in market transactions. Blocks sold included 25,545 shares at a weighted average price of $85.36 and 9,264 shares at a weighted average price of $84.62, among other trades. After these transactions, Devers directly held 17,494 shares of Ionis common stock. The sales were made under a Rule 10b5-1 trading plan adopted on September 3, 2024.

Ionis Pharmaceuticals EVP Research Eric Swayze reported multiple stock option exercises and related share sales on 01/02/2026. He exercised options for 5,125 and 18,338 shares of common stock at an exercise price of $60.89 per share and sold the same numbers of shares at weighted average prices of $78.57 and $79.27, respectively, under a Rule 10b5-1 trading plan.

After these transactions, Swayze held 30,453 Ionis common shares directly and 256 shares indirectly through his son. He also received a new grant of non-qualified stock options for 19,350 shares at an exercise price of $79.67, vesting 25% on 01/02/2027 with the rest vesting in 36 monthly installments over three years, while his son received options for 150 shares on the same terms, reported as indirectly owned.

Ionis Pharmaceuticals executive Patrick R. O'Neil, EVP CLO & General Counsel, received a grant of 19,350 non-qualified stock options on 01/02/2026. Each option gives the right to buy one share of Ionis common stock at an exercise price of $79.67 under the company’s Amended and Restated 2011 Equity Incentive Plan.

None of the options were exercisable on the grant date. Instead, 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. The remaining options will then vest and become exercisable in 36 equal monthly installments over the following three years, creating a four-year total vesting period tied to continued service.

Ionis Pharmaceuticals reported an equity award for its Chief Executive Officer, Brett P. Monia. On 01/02/2026, he received a grant of 85,410 non-qualified stock options under the company’s Amended and Restated 2011 Equity Incentive Plan, with an exercise price of $79.67 per share.

According to the vesting terms, the option was not exercisable on the grant date. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, and the remaining shares will vest in 36 equal monthly installments over the following three years, ending before the option’s 01/01/2036 expiration date.

Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, received a new stock option award. On 01/02/2026 she was granted a non-qualified stock option to buy 9,100 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan.

The option was not exercisable for any shares on the grant date. According to the vesting schedule, 25% of the shares will vest and become exercisable on 01/02/2027, and the remaining shares will vest and become exercisable in 36 equal monthly installments over the following three years.

Ionis Pharmaceuticals reported that its EVP, Finance & CFO, Elizabeth L. Hougen, received a grant of stock options on 01/02/2026 under the company’s Amended and Restated 2011 Equity Incentive Plan. The award covers 25,770 non-qualified stock options with an exercise price of $79.67 per share and was granted at no cost to the executive.

None of the options were exercisable on the grant date. 25% of the options will vest and become exercisable on 01/02/2027, with the remaining options vesting in 36 equal monthly installments over the following three years, and the options are scheduled to expire on 01/01/2036.

Ionis Pharmaceuticals reported a routine equity grant to executive Shannon L. Devers, its EVP and Chief Human Resources Officer. On 01/02/2026, Devers received a non-qualified stock option to buy 19,350 shares of Ionis common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan.

The option was not exercisable for any shares on the grant date. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, with the remaining shares vesting in 36 equal monthly installments over the following three years, ending before the option’s expiration on 01/01/2036.

Ionis Pharmaceuticals executive Brian Birchler received a new stock option grant. On 01/02/2026, he was awarded a non-qualified stock option to buy 19,350 shares of Ionis common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan. The filing shows this as a direct holding of derivative securities.

The option was not exercisable in any amount on the grant date. According to the vesting schedule, 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. The remaining shares will then vest and become exercisable in 36 equal monthly installments over the following three years.

Ionis Pharmaceuticals executive C. Frank Bennett, EVP and Chief Scientific Officer, received a new stock option grant. On 01/02/2026, he was granted a non-qualified stock option to purchase 19,350 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan. The option expires on 01/01/2036. Following this grant, he beneficially owned 19,350 derivative securities related to these options.

The option was not exercisable as of 01/02/2026. Vesting is time-based: 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, with the remaining shares vesting and becoming exercisable in 36 equal monthly installments over the subsequent three years, providing long-term equity-based compensation tied to continued service.

Ionis Pharmaceuticals director reports stock option exercise

A director of Ionis Pharmaceuticals, Inc. (IONS) reported exercising a non-qualified stock option on 11/18/2025. The option, with an exercise price of $24.42 per share and originally scheduled to expire on 06/30/2026, was exercised for 16,000 shares of common stock. Following this transaction, the reporting person holds 16,000 shares of Ionis common stock directly and 64,035 shares indirectly through a trust. The filing notes that the acquired shares resulted from the option exercise before its scheduled expiration.

Ionis Pharmaceuticals director reports option exercises and share sales. On 11/19/2025, the reporting person exercised non-qualified stock options to acquire 12,000 Ionis common shares at $40.05 and 32,000 shares at $63.90. The same day, they sold 12,000 shares and another 32,000 shares at a weighted average price of $72.1325 per share, in multiple trades within a stated price range. After these transactions, the insider beneficially owned 46,086 Ionis shares directly, and both option grants referenced in the filing were fully exercised, leaving no remaining derivative securities from those specific awards.

Ionis Pharmaceuticals (IONS) filed a Form 4 reporting an insider sale. EVP, Corp and Development Ops Brian Birchler sold 8,000 shares of common stock on 11/06/2025 under a pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2024. The transaction was reported as a sale at a weighted average price of $76.1724, with individual trades executed between $76.00 and $76.32.

Following this transaction, Birchler beneficially owns 48,826 shares directly. The filing notes that detailed trade-by-trade pricing information within the range is available upon request.

Ionis Pharmaceuticals (IONS) executive Richard S. Geary, EVP and Chief Development Officer, reported option exercises and related sales on November 5–6, 2025 under a Rule 10b5-1 trading plan adopted May 6, 2025.

He exercised non‑qualified stock options at $56.78 and $60.89 and sold the corresponding shares in multiple transactions at weighted average prices of $75.01, $76.0972, and $75.421 (with ranges disclosed in footnotes). Individual trades included 800 and 801 shares on November 5, and 14,738 and 18,300 shares on November 6. Following these transactions, Geary beneficially owns 59,657 shares directly.

Ionis Pharmaceuticals (IONS) executive Richard S. Geary filed an amended Form 4 to correct share amounts. On 11/03/2025, he exercised stock options for 775 shares at $60.89 and 905 shares at $56.78, then sold 775 and 905 common shares at a $75.054 weighted average price, with trades ranging from $75.00 to $75.25.

Following these transactions, Geary beneficially owned 59,657 common shares directly. The amendment states it corrects the amounts reported in Column 4.

Ionis Pharmaceuticals (IONS): Director stock transactions disclosed. Director Joseph H. Wender reported open-market sales executed under a Rule 10b5-1 trading plan adopted on December 26, 2024. On 10/30/2025, the trust sold 2,484 shares at a weighted average price of $72.19, 8,341 shares at $73.16, and 5,975 shares at $73.85. On 10/31/2025, it sold 11,200 shares at a weighted average price of $75.1586.

Following these transactions, 64,035 shares were beneficially owned indirectly by a trust. The filing notes the reported prices are weighted averages from multiple trades within disclosed ranges, and detailed trade breakdowns are available upon request.

Ionis Pharmaceuticals (IONS): Director transaction reported. On 10/31/2025, director Joseph Loscalzo exercised a non-qualified stock option for 16,000 shares at an exercise price of $52.22 per share and sold 16,000 shares the same day. The reported sale price was a weighted average of $75.1043, with individual trades executed between $75.00 and $75.47.

The option originated from a grant exercisable since 07/03/2018 and expiring on 07/02/2027, and the director reported 0 derivative securities remaining afterward. Following these transactions, direct beneficial ownership was 36,330 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2024.

Ionis Pharmaceuticals (IONS) executive Richard S. Geary, EVP and Chief Development Officer, reported option exercises and related sales. On 10/31/2025 and 11/03/2025, he exercised non-qualified stock options at $60.89 and $56.78, then sold shares pursuant to a Rule 10b5-1 trading plan adopted on May 6, 2025. Weighted average sale prices were $75.1083 (range $75.00–$75.47) and $75.054 (range $75.00–$75.25). Following these transactions, he beneficially owns 59,657 shares directly.